Who are Gefitinib and Pemetrexed/platinum's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gefitinib-and-pemetrexed-platinum.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Gefitinib and Pemetrexed/platinum — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gefitinib and Pemetrexed/platinum (Gefitinib and Pemetrexed/platinum) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: EGFR tyrosine kinase inhibitor combined with antifolate and platinum-based chemotherapy. Area: Oncology.

phase 3 EGFR tyrosine kinase inhibitor combined with antifolate and platinum-based chemotherapy EGFR (gefitinib); thymidylate synthase, dihydrofolate reductase (pemetrexed); DNA (platinum agents) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Gefitinib and Pemetrexed/platinum (Gefitinib and Pemetrexed/platinum) — Sun Yat-sen University. This combination uses gefitinib to inhibit EGFR signaling in lung cancer cells while pemetrexed/platinum chemotherapy provides additional cytotoxic activity through multiple mechanisms.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Gefitinib and Pemetrexed/platinum TARGET	Gefitinib and Pemetrexed/platinum	Sun Yat-sen University	phase 3	EGFR tyrosine kinase inhibitor combined with antifolate and platinum-based chemotherapy	EGFR (gefitinib); thymidylate synthase, dihydrofolate reductase (pemetrexed); DNA (platinum agents)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (EGFR tyrosine kinase inhibitor combined with antifolate and platinum-based chemotherapy class)

Sun Yat-sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Gefitinib and Pemetrexed/platinum — Competitive Intelligence Brief. https://druglandscape.com/ci/gefitinib-and-pemetrexed-platinum. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab